BioSpace News Archive

Business

9 Top Biopharma CEO-to-Employee Pay Gaps

Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.

May 21, 2024
·
9 min read
·
Tristan Manalac
FDA

FDA Greenlights Two Interchangeable Biosimilars to Regeneron’s Eylea

The regulator on Monday approved two interchangeable biosimilars to Regeneron’s Eylea, providing additional competition for the pharma’s blockbuster as key patent protections are set to expire.

May 21, 2024
·
2 min read
·
Tristan Manalac
Business

AstraZeneca Sets $80B Revenue Target, Goal of 20 New Drugs by 2030

AstraZeneca on Tuesday laid out an ambitious plan to boost growth in its existing oncology, biopharma and rare disease portfolios, as well as launch 20 new medicines before the end of the decade.

May 21, 2024
·
2 min read
·
Tristan Manalac
Policy

Opinion: Chinese CDMOs and US Biopharma PR Strike a Precarious Balance

The PR departments of Chinese CDMOs affected by the BIOSECURE Act and their U.S. partners must step up to ensure proposed legislation doesn’t squash innovation.

May 21, 2024
·
5 min read
·
JX (Jaxon) Tan
Business

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer

Valneva SE, a specialty vaccine company, announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer and Executive Committee member, effective June 3, 2024.

May 21, 2024
·
4 min read
Innate Pharma: Clarification Regarding SAR443579 Designation

Innate Pharma SA announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation.

May 21, 2024
·
4 min read
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

. Hansa Biopharma, “Hansa”, announced data featuring imlifidase will be presented at the American Transplant Congress, the joint annual meeting of the American Society of Transplant Surgeons and the American Society of Transplantation.

May 21, 2024
·
7 min read
Policy

GC Biopharma/Novel Pharma’s Sanfilippo Syndrome Treatment Obtains FDA IND Clearance

GC Biopharma and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug application for their jointly developed MPSIIIA treatment, GC1130A.

May 21, 2024
·
2 min read
Drug Development

RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren’s Syndrome

RemeGen Co. Ltd., a commercial-stage biotechnology company, recently announced significant progress of Telitacicept, that two Phase III clinical trials in China for the treatment of IgA nephropathy and primary Sjögren’s syndrome have completed patient enrollments.

May 21, 2024
·
3 min read
Drug Development

Cali Biosciences Announces Publication of Successful Phase 2 Study Results in Hernia

Cali Biosciences Co., Ltd. announced publication of “CPL‑01, an investigational long‑acting ropivacaine, demonstrates safety and efficacy in open inguinal hernia repair” in the scientific journal Hernia.

May 21, 2024
·
3 min read